Your Messages Inbox
Your Article Summary
See Latest ArticlesStandardized Treatment of Active Tuberculosis in Patients with Previous Treatment and/or with Mono-resistance to Isoniazid: A Systematic Review and Meta-analysis
PLoS Medicine, 09/18/09
Menzies D et al. – There is little published evidence to support the continued use of the currently recommended retreatment regimen. There is an urgent need for a concerted international effort to substantially expand access to reliable drug sensitivity testing and to initiate randomized trials in patients with pretreatment drug resistance of all forms, particularly in previously treated patients. While awaiting results of these trials, the standardized retreatment regimen should be redesigned—at minimum to adequately treat patients with isoniazid resistance.
Related Articles
Smoking and Risk of Tuberculosis Incidence, Mortality, and Recurrence in South Korean Men and Women
American Journal of Epidemiology, 11/18/09
Relevance Score: 91%
Implications of the global financial crisis for the response to diseases of poverty within overall health sector development: the case of tuberculosis
Tropical Medicine & International Health, 11/10/09
Relevance Score: 90%
Immunopathogenesis and Diagnosis of Tuberculosis and Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome during Early Antiretroviral Therapy
The Journal of Infectious Diseases, 11/03/09
Relevance Score: 90%
Radiological presentation of pulmonary tuberculosis infected by the W-Beijing Mycobacterium tuberculosis strain
The International Journal of Tuberculosis and Lung Disease, 11/03/09
Relevance Score: 89%
Follow-up results of 702 patients receiving tumor necrosis factor-alpha antagonists and evaluation of risk of tuberculosis
Rheumatology International, 10/29/09
Relevance Score: 89%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09
Prognostic Factors in Idiopathic Pulmonary Fibrosis
The American Journal of the Medical Sciences, 12/17/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Article Search
Sponsor